Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6347285 | 0.90 | POLB (0.51) | TRPM8POLBMAPTALDH1A1KMT2A | |
| SCHEMBL6347280 | 0.88 | MAPT (0.48) | POLBMAPTL3MBTL1ALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL6355505 | 0.84 | MAPT (0.45) | POLBMAPTL3MBTL1ALDH1A1KMT2A | |
| SCHEMBL6346836 | 0.84 | KDM4E (0.42) | POLBMAPTL3MBTL1ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL6354143 | 0.83 | ACHE (0.46) | POLBMAPTL3MBTL1ALDH1A1KMT2A | |
| SCHEMBL6346782 | 0.83 | CYP3A4 (0.39) | POLBMAPTL3MBTL1ALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL6346769 | 0.82 | MAPT (0.43) | MAPTL3MBTL1ALDH1A1KMT2A | |
| SCHEMBL6346963 | 0.82 | ACHE (0.52) | POLBMAPTKMT2A | |
| SCHEMBL6354873 | 0.82 | EPHX2 (0.44) | MAPTL3MBTL1ALDH1A1 | |
| SCHEMBL6343706 | 0.81 | EPHX2 (0.40) | MAPTL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6878725-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040242656-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-12-02 | — | — | US | disclosed |
| EP-1289950-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030078438-A1 | Serine protease inhibitors | ELI LILLY AND COMPANY | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078438-A1 | Serine protease inhibitors | HPN, LPXN, PRSS1 | TRPM8 4027/4885POLB 4589/4885MAPT 4821/4885 |
| US-20040242656-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | TRPM8 4280/4885POLB 4543/4885MAPT 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.